Cargando…

Id-1: Regulator of EGFR and VEGF and potential target for colorectal cancer therapy

BACKGROUND: The helix-loop-helix transcription factor Id-1 (an inhibitor of differentiation and DNA binding) plays a role in development and progression of many tumours. Id-1 is known to exert its effects on the epidermal growth factor receptor (EGFR) and the vascular endothelial growth factor (VEGF...

Descripción completa

Detalles Bibliográficos
Autores principales:	Meteoglu, Ibrahim, Meydan, Nezih, Erkus, Muhan
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2008
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2588562/ https://www.ncbi.nlm.nih.gov/pubmed/19014499 http://dx.doi.org/10.1186/1756-9966-27-69

Ejemplares similares

NF-KappaB expression correlates with apoptosis and angiogenesis in clear cell renal cell carcinoma tissues
por: Meteoglu, Ibrahim, et al.
Publicado: (2008)

Nuclear Factor Kappa B, Matrix Metalloproteinase-1, p53, and Ki-67 Expressions in the Primary Tumors and the Lymph Node Metastases of Colorectal Cancer Cases
por: Meteoglu, Ibrahim, et al.
Publicado: (2015)

Dual EGFR inhibition in combination with anti-VEGF treatment in colorectal cancer
por: Falchook, Gerald S., et al.
Publicado: (2014)

Simultaneous Detection of EGFR and VEGF in Colorectal Cancer using Fluorescence-Raman Endoscopy
por: Kim, Yong-il, et al.
Publicado: (2017)

EGFR-Based Targeted Therapy for Colorectal Cancer—Promises and Challenges
por: Janani, Balakarthikeyan, et al.
Publicado: (2022)

Intrapleural targeted therapies (anti-VEGF and anti-EGFR) in the model of malignant pleural effusion
por: Acencio, Milena Marques Pagliarelli, et al.
Publicado: (2017)

Subsequent anti-VEGF therapy after first-line anti-EGFR therapy improved overall survival of patients with metastatic colorectal cancer
por: Qiu, Tianzhu, et al.
Publicado: (2018)

Relapse with isolated peritoneal metastasis in lung adenocarcinoma: case report and review of the literature
por: Tanriverdi, Ozgur, et al.
Publicado: (2013)

VEGF-A, VEGF-C, VEGF-R2, EGFR and HER2 in serum plus EGFR in tissue of patients with triple-negative breast cancer
por: Iosifidou, R, et al.
Publicado: (2009)

The Association of Alternate VEGF Ligands with Resistance to Anti-VEGF Therapy in Metastatic Colorectal Cancer
por: Lieu, Christopher H., et al.
Publicado: (2013)

Arterial Stiffness in Breast Cancer Patients Treated with Anthracycline and Trastuzumab-Based Regimens
por: Yersal, Özlem, et al.
Publicado: (2018)

Individualized therapies in colorectal cancer: KRAS as a marker for response to EGFR-targeted therapy
por: Chang, David Z, et al.
Publicado: (2009)

Peritoneal VEGF-A expression is regulated by TGF-β1 through an ID1 pathway in women with endometriosis
por: Young, Vicky J., et al.
Publicado: (2015)

Id-1 stimulates cell proliferation through activation of EGFR in ovarian cancer cells
por: Zhang, X, et al.
Publicado: (2004)

Non-Coding RNAs Regulate the Resistance to Anti-EGFR Therapy in Colorectal Cancer
por: Chu, Jinjin, et al.
Publicado: (2022)

Optimizing the use of anti VEGF targeted therapies in patients with metastatic colorectal cancer: review of literature
por: HOPIRTEAN, CLAUDIU, et al.
Publicado: (2018)

Optimizing sequential treatment with anti-EGFR and VEGF mAb in metastatic colorectal cancer: current results and controversies
por: Chen, Datian, et al.
Publicado: (2019)

Vitamin C Restricts the Emergence of Acquired Resistance to EGFR-Targeted Therapies in Colorectal Cancer
por: Lorenzato, Annalisa, et al.
Publicado: (2020)

Mechanisms of resistance to EGFR-targeted therapies in colorectal cancer: more than just genetics
por: Parseghian, Christine, et al.
Publicado: (2023)

Anti-EGFR therapy in metastatic colorectal cancer: mechanisms and potential regimens of drug resistance
por: Li, Qing-Hai, et al.
Publicado: (2020)

Id1 and Id3 expression is associated with increasing grade of prostate cancer: Id3 preferentially regulates CDKN1B
por: Sharma, Pankaj, et al.
Publicado: (2012)

Mechanisms of resistance to anti-EGFR therapy in colorectal cancer
por: Zhao, Ben, et al.
Publicado: (2016)

Phytochemicals Targeting VEGF and VEGF-Related Multifactors as Anticancer Therapy
por: Parveen, Amna, et al.
Publicado: (2019)

Nearly Complete Response of Brain Metastases from HER2 Overexpressing Breast Cancer with Lapatinib and Capecitabine after Whole Brain Irradiation
por: Oktay, Esin, et al.
Publicado: (2013)

Cancer-related CD15/FUT4 overexpression decreases benefit to agents targeting EGFR or VEGF acting as a novel RAF-MEK-ERK kinase downstream regulator in metastatic colorectal cancer
por: Giordano, Guido, et al.
Publicado: (2015)

Migraine headaches among university students using id migraine test as a screening tool
por: Oztora, Serdar, et al.
Publicado: (2011)

Elevated IGFIR expression regulating VEGF and VEGF-C predicts lymph node metastasis in human colorectal cancer
por: Zhang, Chunhui, et al.
Publicado: (2010)

Association of BMI with overall survival in patients with mCRC who received chemotherapy versus EGFR and VEGF-targeted therapies
por: Patel, Gargi S, et al.
Publicado: (2015)

Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies
por: Leto, Simonetta M., et al.
Publicado: (2014)

ATM mutations and E-cadherin expression define sensitivity to EGFR-targeted therapy in colorectal cancer
por: Geißler, Anna-Lena, et al.
Publicado: (2017)

Current concepts of anti-EGFR targeting in metastatic colorectal cancer
por: Doleschal, Bernhard, et al.
Publicado: (2022)

Nanobody-Based EGFR-Targeting Immunotoxins for Colorectal Cancer Treatment
por: Narbona, Javier, et al.
Publicado: (2023)

Silencing NIK potentiates anti-VEGF therapy in a novel 3D model of colorectal cancer angiogenesis
por: Maracle, Chrissta X., et al.
Publicado: (2018)

Endoglin (CD105) and VEGF as potential angiogenic and dissemination markers for colorectal cancer
por: Nogués, Ana, et al.
Publicado: (2020)

VEGF: Potential therapy for renal regeneration
por: Chade, Alejandro R.
Publicado: (2012)

Tumour-infiltrating neutrophils counteract anti-VEGF therapy in metastatic colorectal cancer
por: Schiffmann, Lars Mortimer, et al.
Publicado: (2018)

VEGF, EGFR and PSMA as possible imaging targets of lymph node metastases of urothelial carcinoma of the bladder
por: van der Fels, Christa Anne Maria, et al.
Publicado: (2022)

Evaluation of Second-Line Anti-VEGF after First-Line Anti-EGFR Based Therapy in RAS Wild-Type Metastatic Colorectal Cancer: The Multicenter “SLAVE” Study
por: Parisi, Alessandro, et al.
Publicado: (2020)

Inhibitor of Differentiation 1 (Id1) in Cancer and Cancer Therapy
por: Zhao, Zhengxiao, et al.
Publicado: (2020)

Novel Somatic Genetic Variants as Predictors of Resistance to EGFR-Targeted Therapies in Metastatic Colorectal Cancer Patients
por: Riera, Pau, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_st3hv3ijt23m8khjp6sikgjgsk